ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > AGM

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Jul 02, 2021 10:29am

150 Views

Post# 33481626

RE:AGM

This is good news, in that the majority of existing shareholders are good with the current leadership and indirectly the business plan. I presume most of those voting have more DD and skin in the game than me.

there are a significant votes against Williams and Wyman, though relative to the others. Makes sense as they are the ones at the negotiating table and some investors have lost confidence due to the delays.

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?